Shalini Sharp currently serves on the Boards of Directors of Neurocrine Biosciences, Organon & Co and BeiGene. Previously, Ms. Sharp served as Chief Financial Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases, and Chief Financial Officer at Agenus, a clinical-stage immune-oncology company. Earlier, Ms. Sharp held positions at Elan Pharmaceuticals, McKinsey & Company, and Goldman Sachs.
Ms. Sharp received her AB from Harvard College and her MBA from Harvard Business School.